| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 31.24% | Needham | → $62 | Reiterates | Buy → Buy |
| 10/23/2023 | 31.24% | Needham | $71 → $62 | Maintains | Buy |
| 09/06/2023 | 10.08% | HSBC | → $52 | Initiates Coverage On | → Hold |
| 07/27/2023 | 31.24% | Baird | $56 → $62 | Maintains | Outperform |
| 07/27/2023 | 20.66% | Barclays | $51 → $57 | Maintains | Equal-Weight |
| 07/26/2023 | 50.3% | Needham | $63 → $71 | Reiterates | Buy → Buy |
| 07/19/2023 | 18.54% | Baird | → $56 | Initiates Coverage On | → Neutral |
| 05/08/2023 | 7.96% | Barclays | $45 → $51 | Maintains | Equal-Weight |
| 05/03/2023 | 33.36% | Needham | $77 → $63 | Maintains | Buy |
| 04/17/2023 | 63% | Needham | → $77 | Reiterates | → Buy |
| 04/14/2023 | 1.61% | Mizuho | → $48 | Initiates Coverage On | → Neutral |
| 04/13/2023 | 1.61% | Mizuho | → $48 | Initiates Coverage On | → Neutral |
| 12/21/2022 | 31.24% | Barclays | → $62 | Initiates Coverage On | → Equal-Weight |
| 11/23/2022 | 33.36% | Goldman Sachs | $73 → $63 | Maintains | Buy |
| 11/02/2022 | 63% | Needham | $88 → $77 | Maintains | Buy |
| 08/16/2022 | 54.53% | Goldman Sachs | $85 → $73 | Maintains | Buy |
| 08/04/2022 | 86.28% | Needham | $106 → $88 | Maintains | Buy |
| 05/05/2022 | 109.57% | Piper Sandler | $104 → $99 | Maintains | Overweight |
| 04/06/2022 | 101.1% | Wolfe Research | → $95 | Initiates Coverage On | → Outperform |
| 02/24/2022 | 103.22% | UBS | → $96 | Upgrades | Neutral → Buy |
| 02/24/2022 | 124.39% | Needham | $120 → $106 | Maintains | Buy |
| 12/03/2021 | 128.62% | Goldman Sachs | → $108 | Initiates Coverage On | → Buy |
| 11/03/2021 | 154.02% | Needham | $117 → $120 | Maintains | Buy |
| 08/20/2021 | 147.67% | Needham | $104 → $117 | Maintains | Buy |
| 08/17/2021 | 122.27% | Baird | $100 → $105 | Maintains | Outperform |
| 07/20/2021 | 96.87% | Needham | → $93 | Upgrades | Hold → Buy |
| 06/02/2021 | 107.45% | Piper Sandler | $99 → $98 | Maintains | Overweight |
| 04/13/2021 | 94.75% | Piper Sandler | $81 → $92 | Maintains | Overweight |
| 03/03/2021 | 77.82% | Berenberg | → $84 | Downgrades | Buy → Hold |
| 01/05/2021 | — | Needham | Downgrades | Buy → Hold | |
| 09/02/2020 | 16.43% | Baird | → $55 | Initiates Coverage On | → Outperform |
| 07/29/2020 | 43.95% | Needham | $76 → $68 | Maintains | Buy |
| 06/26/2020 | 60.88% | Needham | $84 → $76 | Maintains | Buy |
| 04/30/2020 | 5.84% | Canaccord Genuity | $66 → $50 | Maintains | Hold |
| 04/30/2020 | 20.66% | UBS | $70 → $57 | Maintains | Neutral |
| 03/24/2020 | -15.33% | Stifel | $80 → $40 | Maintains | Buy |
| 11/28/2018 | 122.27% | UBS | → $105 | Initiates Coverage On | → Neutral |
What is the target price for LivaNova (LIVN)?
The latest price target for LivaNova (NASDAQ: LIVN) was reported by Needham on November 17, 2023. The analyst firm set a price target for $62.00 expecting LIVN to rise to within 12 months (a possible 31.24% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LivaNova (LIVN)?
The latest analyst rating for LivaNova (NASDAQ: LIVN) was provided by Needham, and LivaNova reiterated their buy rating.
When is the next analyst rating going to be posted or updated for LivaNova (LIVN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LivaNova, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LivaNova was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
Is the Analyst Rating LivaNova (LIVN) correct?
While ratings are subjective and will change, the latest LivaNova (LIVN) rating was a reiterated with a price target of $0.00 to $62.00. The current price LivaNova (LIVN) is trading at is $47.24, which is within the analyst's predicted range.